Table 1 Clinical characteristics of patients at baseline
Parameters | Entire cohort (N = 901) | Common (n = 366) | Severe (n = 411) | Critical (n = 124) | P value |
|---|---|---|---|---|---|
Age, years (median, IQR) | 60.0 (49.0–69.0) | 54.0 (42.8–62.0) | 64.0 (52.0–71.0) | 68.5 (58.0–78.0) | < 0.001 |
Sex-n, % | 0.015 | ||||
Male | 435 (48.3) | 161 (44.0) | 201 (48.9) | 73 (58.9) | |
Female | 466 (51.7) | 205 (56.0) | 210 (51.1) | 51 (41.1) | |
Coexisting disorders-n, % | 509 (56.5) | 171 (46.7) | 245 (59.6) | 93 (75.0) | < 0.001 |
Hypertension | 289 (32.1) | 82 (22.4) | 149 (36.3) | 58 (46.8) | < 0.001 |
Diabetes mellitus | 126 (14.0) | 38 (10.4) | 57 (13.9) | 31 (25.0) | < 0.001 |
Chronic obstructive lung disease | 17 (1.9) | 3 (0.8) | 7 (1.7) | 7 (5.6) | < 0.001 |
Hemorrhagic or ischemic stroke | 38 (4.2) | 6 (1.6) | 15 (3.6) | 17 (13.7) | < 0.001 |
History of tuberculosis | 13 (1.4) | 4 (1.1) | 5 (1.2) | 4 (3.2) | 0.002 |
Autoimmune diseases | 10 (1.1) | 4 (1.1) | 4 (1.0) | 2 (1.6) | 0.49 |
Chronic kidney disease | 13 (1.4) | 0 (0) | 3 (0.7) | 10 (8.1) | < 0.001 |
Malignancies | 22 (2.4) | 8 (2.2) | 13 (3.2) | 1 (0.8) | 0.30 |
Coronary artery disease | 73 (8.1) | 18 (4.9) | 37 (9.0) | 18 (14.5) | 0.002 |
Chronic dialysis | 7 (0.8) | 0 (0) | 2 (0.5) | 5 (4.0) | < 0.001 |
Baseline IL-6 | < 0.001 | ||||
Normal-n, % | 708 (78.6) | 347 (94.8) | 329 (80.0) | 32 (25.8) | |
Elevateda-n, % | 193 (21.4) | 19 (5.2) | 82 (20.0) | 92 (74.2) | |
Tocilizumab used-n, % | 16 (1.8) | 4 (1.1) | 7 (1.7) | 5 (4) | 0.39 |
Outcomesb-n, % | < 0.001 | ||||
Cured/discharged | 683 (75.8) | 290 (79.2) | 340 (82.7) | 53 (42.7) | < 0.001 |
Continued hospitalization | 193 (21.4) | 76 (20.8) | 70 (17.0) | 47 (37.9) | < 0.001 |
Death | 24 (2.7) | 0 (0) | 0 (0) | 24 (19.4) | < 0.001 |